Haleon SEC Filings

Haleon plc filed a Form 6-K notifying investors that Tracy Clarke, a current Non-Executive Director of Haleon, will be appointed as a Non-Executive Director of Inchcape plc effective 31 December 2025. The disclosure was made to satisfy paragraph 6.4.9R(2) of the UK Listing Rules and is presented as a director declaration in the exhibit. The report is dated 02 October 2025 and signed by Amanda Mellor, Company Secretary. The filing reiterates Haleon’s consumer health focus and lists major product categories and brands for context.

Haleon plc has announced the purchase of 1,561,229 ordinary shares under the second tranche of its share buyback programme and intends to hold these shares as treasury stock. After settlement, the company's registered share capital is 8,952,353,648 ordinary shares of £0.01 each, with 45,962,012 held as treasury shares, leaving 8,906,391,636 voting shares. The announcement confirms completion of the final tranche of the buyback programme launched 28 March 2025. Since the start of the year, including shares acquired from Pfizer, Haleon repurchased 175,806,525 shares: 131,372,271 were cancelled and 44,434,254 remain as treasury shares. A full trade breakdown is available via the provided link.

Haleon plc reports its total issued share capital and voting rights as of 30 September 2025. The company has 8,952,353,648 ordinary shares of £0.01 each, of which 44,400,783 are held in treasury, leaving 8,907,952,865 ordinary shares with voting rights. Shareholders and others with notification obligations should use 8,907,952,865 as the denominator when assessing disclosure thresholds under the FCA's Transparency Rules. The filing provides a contact for notifiable interests (company.secretary@haleon.com) and a brief company description of Haleon’s consumer health business and major brands.

Haleon plc reports the purchase of 1,500,000 ordinary shares of £0.01 each under the second tranche of its share buyback programme announced 31 July 2025. The shares were bought on the London Stock Exchange/CBOE on 30 September 2025 at an average price of 331.3782 pence per share and will be held as treasury shares. After settlement the companys registered share capital is 8,952,353,648 ordinary shares, of which 44,400,783 are treasury shares, leaving 8,907,952,865 shares with voting rights. The announcement directs readers to a full breakdown of individual trades online.

Haleon plc announced the purchase of 1,996,340 ordinary shares under the second tranche of its buyback programme. The trades executed on the London Stock Exchange on 29 September 2025 at an average price of £330.3042 per share. The company intends to hold the purchased shares as treasury shares.

After settlement, registered share capital is 8,952,353,648 ordinary shares of £0.01 each, of which 42,900,783 are treasury shares, leaving 8,909,452,865 ordinary shares with voting rights. A full breakdown of individual trades is available at the provided RNS link and on the company's investor website.

Haleon plc announced on 29 September 2025 that it purchased 1,996,340 ordinary shares of £0.01 each under the second tranche of its share buyback programme announced 31 July 2025. Trades executed on the London Stock Exchange/CBOE (UK)/CXE on 26 September 2025 show prices reported between £325.1000 and £328.7000 with an average of £327.6614. The Company intends to hold the purchased shares as treasury shares. After settlement, registered share capital is 8,952,353,648 ordinary shares, of which 40,904,443 are treasury shares, leaving 8,911,449,205 ordinary shares with voting rights. A full trade breakdown is available via the provided RNS link and the Company website.

Haleon plc filed a Form 6-K reporting a notification of transactions by persons discharging managerial responsibilities (PDMRs) under the UK Market Abuse Regulation. The notice, dated 26 September 2025, discloses a transaction price of £3.31963. The filing lists the company’s well-known brands including Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren and directs readers to the corporate website. The report provides the required public disclosure of insider activity but does not include clear aggregated volume figures in the provided text, limiting assessment of the transaction’s size or investor impact.

Haleon plc reports a purchase of 2,318,700 ordinary shares under the second tranche of its share buyback programme. The trades occurred on the London Stock Exchange/CBOE (UK)/CXE on 25 September 2025 with reported trade price points shown as 329.7000, 325.9000 and a weighted average of 327.8536. The Company intends to hold the purchased shares as treasury shares. After settlement, registered share capital is 8,952,353,648 ordinary shares of £0.01 each, of which 38,908,103 are held as treasury shares, leaving 8,913,445,545 ordinary shares with voting rights. A full breakdown of individual trades is available via the provided RNS link and on the Company website.

Haleon plc announced on 25 September 2025 the purchase of 3,251,858 ordinary shares of £0.01 each under the second tranche of its share buyback programme announced 31 July 2025. The purchases included 3,101,999 shares executed on 24 September 2025 on the London Stock Exchange CBOE (UK)/CXE at an average price of £330.4723 per share as shown in the trade breakdown. The Company intends to hold the acquired shares as treasury shares. After settlement the registered share capital is 8,952,353,648 ordinary shares, of which 36,589,403 are treasury shares, leaving 8,915,764,245 ordinary shares with voting rights for FCA disclosure guidance purposes. A full breakdown of individual trades is available at the provided RNS link and on the Company website.